LEXEO THERAPEUTICS IN

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

12 5 2025 07:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

01 5 2025 09:16:04 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

07 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

24 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

19 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

13 11 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

30 10 2024 06:14:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

22 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

05 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

12 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

15 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

11 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

08 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

09 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

07 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

22 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

16 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

13 3 2024 16:22:39 提供 Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

11 3 2024 07:42:39 提供 Nasdaq GlobeNewswire